secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2022-02-01T23:59:59+00:00
Accession:  0001193125-22-024600
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology CFO Marc Grasso resigns; Doyle named principal accounting officer, CEO Wilson principal financial officer
--------------------------------------------------------------------------------

- CFO Marc Grasso resigns effective Feb 4, 2022 for family reasons; will provide up to 3 months advisory services with equity vesting.
- Thomas Doyle appointed SVP Finance & Accounting/principal accounting officer effective Feb 7; base salary $333,500, bonus up to 35%, option for 39,281 shares and 8,390 RSUs.
- CEO Troy Wilson appointed principal financial officer effective Feb 7.
- Doyle's option vests over 48 months; RSU vests over 4 years; severance includes 9 months salary plus COBRA.
- If within 12 months of change of control, Doyle receives lump sum of 9 months salary plus full target bonus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312522024600/0001193125-22-024600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312522024600/d661588d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-024600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer